This is a working overview of lyophilisation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-21. Anything still debated is marked as such rather than presented as settled.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Compound class | Synthetic tetrapeptide | Not a natural free peptide |
| Research origin | Russian gerontology institutes | Developed during the 1990s |
| Main research claim | Telomerase activation | Evidence mainly from cultured cells |
| Regulatory status | Not an approved drug | Handled as a research material |
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity confirmation uses mass spectrometry, usually electrospray ionisation in positive mode or matrix-assisted laser desorption. The protonated free peptide produces a signal near three hundred and ninety-one daltons, while salt adducts shift that value slightly. Tandem mass spectrometry or amino acid analysis supplies sequence-level confirmation, which a single mass measurement cannot. Peptides containing aspartate can cyclise into succinimide intermediates that hydrolyse to isoaspartate isomers of identical mass. Because those isomers are difficult to separate chromatographically, identity and purity results carry more weight when interpreted together.
Storage practice centres on limiting moisture, oxygen, and repeated temperature cycling. Freeze-dried powder is generally held desiccated at minus twenty degrees Celsius or colder and protected from light. Reconstituted solutions are markedly less stable, and the aspartate-glycine junction is prone to succinimide formation at neutral to mildly alkaline pH. Portioning material into single-use aliquots reduces degradation compared with repeated freeze-thaw cycles. Stability data specific to this tetrapeptide remain scarce, so most handling guidance is extrapolated from general peptide chemistry rather than measured directly.
An active celebrity in the climate change movement, DiCaprio believes global warming is the world's "number-one environmental challenge". Eager to learn about ecology from an early age, he would watch documentaries on rainforest depletion and the loss of species and habitats. In 1998, he established the Leonardo DiCaprio Foundation, a non-profit organization devoted to promoting environmental awareness. It supports organizations and campaigns committed to ensuring a viable future for planet Earth, and produced the short web documentaries Water Planet and Global Warning. The foundation has also funded debt-for-nature swaps. By 2018, the foundation had funded more than 200 projects, providing $100 million in support. He has been an active supporter of numerous environmental organizations and sat on the board of the World Wildlife Fund and International Fund for Animal Welfare. DiCaprio has owned environment-friendly electric-hybrid vehicles. His use of private jets and large yachts have been criticized as hypocritical due to their large carbon footprints. DiCaprio chaired the national Earth Day celebration in 2000 where he interviewed Bill Clinton and they discussed plans to deal with global warming and the environment. He presented at the 2007 American leg of Live Earth. DiCaprio donated $1 million to the Wildlife Conservation Society at Russia's Tiger Summit. DiCaprio's persistence in reaching the event after encountering two plane delays caused then Prime Minister Vladimir Putin to describe him as a "muzhik" or "real man".
=== Stages of healing === The graft is carefully spread on the bare area to be covered. It is held in place by a few small stitches or surgical staples. The healing process for skin grafts typically occurs in three stages: plasmatic imbibition, capillary inosculation, and neovascularization. During the first 24 hours, the graft is initially nourished by a process called plasmatic imbibition in which the graft "drinks plasma" (i.e., absorbs nutrients from the underlying recipient bed). Between 2 and 3 days, new blood vessels begin growing from the recipient area into the transplanted skin in a process called capillary inosculation. Between 4 and 7 days, neovascularization occurs in which new blood vessels form between the graft and the recipient tissues.
=== Combined with statins === Extended release nicotinic acid was combined with lovastatin (Advicor), and with simvastatin (Simcor), as prescription drug combinations. The combination niacin/lovastatin was approved by the US Food and Drug Administration (FDA) in 2001. The combination niacin/simvastatin was approved by the FDA in 2008. Subsequently, large outcome trials using these nicotinic acid and statin therapies were unable to demonstrate incremental benefit of nicotinic acid beyond statin therapy alone. The FDA withdrew approval of both drugs in 2016. The reason given: "Based on the collective evidence from several large cardiovascular outcome trials, the Agency has concluded that the totality of the scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events." The drug company discontinued the drugs.
==== Vitamin D2 ==== Plants Alfalfa (Medicago sativa subsp. sativa), shoot: 4.8 μg (192 IU) vitamin D2, 0.1 μg (4 IU) vitamin D3 Fungus, from USDA nutrient database, per 100 g: Mushrooms, portabella, exposed to ultraviolet light, raw: Vitamin D2: 11.2 μg (446 IU) Mushrooms, portabella, exposed to ultraviolet light, grilled: Vitamin D2: 13.1 μg (524 IU) Mushrooms, shiitake, dried: Vitamin D2: 3.9 μg (154 IU) Mushrooms, shiitake, raw: Vitamin D2: 0.4 μg (18 IU) Mushrooms, portabella, raw: Vitamin D2: 0.3 μg (10 IU) Mushroom powder, any species, illuminated with sunlight or artificial ultraviolet light sources Vitamin D2, or ergocalciferol is found in fungus (except alfalfa which is a plantae) and created from viosterol, which in turn is created when ultraviolet light activates ergosterol (which is found in fungi and named as a sterol from ergot). Any UV-irradiated fungus including yeast form vitamin D2. Human bioavailability of vitamin D2 from vitamin D2-enhanced button mushrooms via UV-B irradiation is effective in improving vitamin D status and not different from a vitamin D2 supplement according to study. For example, vitamin D2 from UV-irradiated yeast baked into bread is bioavailable. By visual assessment or using a chromometer, no significant discoloration of irradiated mushrooms, as measured by the degree of "whiteness", was observed making it hard to discover if they have been treated without labeling. Claims have been made that a normal serving (approx.
Sources: en.wikipedia.org
Kenan Christopher Garcia (also known as K. Christopher Garcia) is an American scientist known for his research on the molecular and structural biology of cell surface receptors. Garcia is a professor in the Departments of Molecular and Cellular Physiology and Structural Biology at the Stanford University School of Medicine, an Investigator of the Howard Hughes Medical Institute and a member of the National Academies of Science and Medicine. In addition to his role at Stanford, Garcia is a co-founder of several biotechnology companies, including Alexo Therapeutics, Surrozen, and 3T Biosciences.
=== Humoral hypercalcemia of malignancy === PTHrP is related in function to parathyroid hormone (PTH). When a tumor secretes PTHrP, this can lead to hypercalcemia. As this is sometimes the first sign of the malignancy, hypercalcemia caused by PTHrP is considered a paraneoplastic phenomenon. PTHrP is responsible for most cases of humoral hypercalcemia of malignancy. PTHrP shares the same N-terminal end as parathyroid hormone and therefore it can bind to the same receptor, the Type I PTH receptor (PTHR1). PTHrP can simulate most of the actions of PTH including increases in bone resorption and distal tubular calcium reabsorption, and inhibition of proximal tubular phosphate transport. PTHrP lacks the normal feedback inhibition as PTH. However, PTHrP has a less sustained action than PTH on PTHR1 activation, which may explain at least in part its reduced ability to stimulate 1,25-dihydroxyvitamin D (1,25(OH)2 vitamin D) production and indirectly intestinal calcium absorption through an action to increase circulating levels of 1,25(OH)2 vitamin D.
A Matter of Honour: An Account of the Indian Army, its Officers and Men. Macmillan. McCosh, John (1856). Advice to Officers in India (revised ed.). London: Wm. H. Allen & Co. Omissi, David (1994). The Sepoy and the Raj: The Indian Army, 1860–1940. London: Macmillan. Roy, Pinaki. "Black Peepers who charged: Remembering the British-Indian Military Personnel of the Two World Wars". Modernity of India: Ambiguities and Deformities. Eds. Sarkar, A.K., K. Chakraborty, and M. Dutta. Kolkata: Setu Prakashani, 2014 (ISBN 978-93-80677-68-2). pp. 181–96.
Sources: en.wikipedia.org
=== Cancer therapy === In magnetic fluid hyperthermia, nanoparticles of different types like Iron oxide, magnetite, maghemite or even gold are injected in tumor and then subjected under a high frequency magnetic field. These nanoparticles produce heat that typically increases tumor temperature to 40-46 °C, which can kill cancer cells. Another major potential of magnetic nanoparticles is the ability to combine heat (hyperthermia) and drug release for a cancer treatment. Numerous studies have shown particle constructs that can be loaded with a drug cargo and magnetic nanoparticles. The most prevalent construct is the "Magnetoliposome", which is a liposome with magnetic nanoparticles typically embedded in the lipid bilayer. Under an alternating magnetic field, the magnetic nanoparticles are heated, and this heat permeabilizes the membrane. This causes release of the loaded drug. This treatment option has a lot of potential as the combination of hyperthermia and drug release is likely to treat tumors better than either option alone, but it is still under development.
Tablets offer several advantages over coffee, tea, and other caffeinated beverages, including convenience, known dosage, and avoidance of concomitant intake of sugar or acids. The use of caffeine in this form may increase alertness. These tablets are commonly used by students studying for their exams and by people who work or drive for long hours.
=== Literature === In Mary Shelley's novel Frankenstein (1818), Victor Frankenstein takes laudanum as his only means of sleeping and thus preserving his life while in recovery from months of fever and a series of horrible events. A laudanum-addicted character also appeared in Wilkie Collins' novel Armadale (1864–1866). Wilkie Collins' novel The Moonstone (1868) features laudanum "as an essential ingredient of the plot." Collins based his description of the drug's effects on his own experiences with it. Laudanum appears in Charles Baudelaire's prose poem The Double Room, published in his collection Le Spleen de Paris in 1869. Laudanum is portrayed as the surgical drug of choice for fifteenth-century physicians in Lawrence Schoonover's novel The Burnished Blade (1948), the plot of which deals in part with the smuggling of expensive raw opium into France from the Empire of Trebizond. Stephen Maturin, one of the main characters in Patrick O'Brian's Aubrey–Maturin series of novels (1969–2004) about the Napoleonic wars, is a sometime laudanum addict.
== Adverse effects == Adverse effects associated with the MMR vaccine include fever, rash, injection site pain, and, in rare cases, red or purple discolorations on the skin known as thrombocytopenic purpura, or seizures related to fever (febrile seizure).
Sources: en.wikipedia.org
Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.
That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.
It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.